Sign In
Buy OGEN
$0.610
+0 (+0%)
At Close: Jun 03, 2026
Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”
Stocks closed down on Wednesday as the economic numbers are starting to show just how weak the economy is becoming, but a drop in jobless claims (to 5.25 million) has allowed stocks to rise less than
Analysts' Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN), Dicerna Pharma (DRNA) and Oragenics (OGEN)
11:17am, Thursday, 16'th Apr 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Urogen Pharma (URGN), Dicerna Pharma (DRNA) and Oragenics
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Urogen Pharma (URGN
The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
12:03pm, Wednesday, 15'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-Week Highs April 14)
Bio-Rad Laboratories, Inc...
Oragenics Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
06:03pm, Sunday, 05'th Apr 2020
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts...
Analysts Are Bullish on Top Healthcare Stocks: Cassiopea SpA (CPPSF), Oragenics (OGEN)
11:16am, Tuesday, 31'st Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassiopea SpA (CPPSF), Oragenics (OGEN) and CytomX
OGEN: Results from Phase 2 Trial of AG013 in Early 2Q20…
02:50pm, Monday, 09'th Mar 2020
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Topline Data for Phase 2 Trial of AGO13 in Oral Mucositis in Early 2Q20 Oragenics, Inc. (NYSE:OGEN) is currently conduc
We're Keeping An Eye On Oragenics's (NYSEMKT:OGEN) Cash Burn Rate
04:16pm, Tuesday, 10'th Dec 2019
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019
01:30pm, Tuesday, 03'rd Dec 2019
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D.,
OGEN: AG013 Phase 2 Trial Enrollment Complete…
02:45pm, Monday, 02'nd Dec 2019
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a
